Erik Harris Ultragenyx Pharmaceutical Inc. (RARE) insider trading activity

Erik Harris is EVP & Chief Commercial Officer of Ultragenyx Pharmaceutical Inc.. Currently has a direct ownership of 67,163 shares of RARE, which is worth approximately $2.84 Million. The most recent transaction as insider was on Mar 01, 2024, when has been sold 4,768 shares (Common Stock) at a price of $53.76 per share, resulting in proceeds of $256,327. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 67.2K

0% 3M change

30.97% 12M change

Total Value Held $2.84 Million

Erik Harris Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Mar 01 2024	SELL Open market or private sale	$256,327 $53.76 p/Share	4,768 Reduced 6.63%	67,163 Common Stock
Mar 01 2024	BUY Grant, award, or other acquisition	-	20,357 Added 22.13%	71,638 Common Stock
Sep 05 2023	SELL Open market or private sale	$227,760 $37.96 p/Share	6,000 Reduced 10.47%	51,281 Common Stock
Jun 19 2023	SELL Open market or private sale	$14,701 $48.2 p/Share	305 Reduced 0.53%	57,281 Common Stock
Mar 01 2023	SELL Open market or private sale	$165,796 $45.25 p/Share	3,664 Reduced 6.01%	57,344 Common Stock
Mar 01 2023	BUY Grant, award, or other acquisition	-	24,663 Added 28.85%	60,823 Common Stock
Jun 19 2022	SELL Open market or private sale	$16,160 $54.78 p/Share	295 Reduced 0.81%	36,160 Common Stock
Mar 01 2022	SELL Open market or private sale	$180,740 $66.62 p/Share	2,713 Reduced 10.84%	22,317 Common Stock
Mar 01 2022	BUY Grant, award, or other acquisition	-	14,000 Added 27.82%	36,317 Common Stock
Oct 14 2021	SELL Open market or private sale	$24,585 $81.14 p/Share	303 Reduced 1.2%	25,030 Common Stock
Jul 06 2021	SELL Open market or private sale	$34,324 $91.53 p/Share	375 Reduced 1.46%	25,333 Common Stock
Jun 21 2021	SELL Open market or private sale	$54,317 $94.96 p/Share	572 Reduced 2.18%	25,708 Common Stock
Jun 19 2021	SELL Open market or private sale	$41,353 $94.63 p/Share	437 Reduced 1.64%	26,280 Common Stock
May 07 2021	SELL Open market or private sale	$44,672 $113.67 p/Share	393 Reduced 1.45%	26,717 Common Stock
May 06 2021	SELL Open market or private sale	$34,900 $113.68 p/Share	307 Reduced 1.12%	27,110 Common Stock
Apr 20 2021	SELL Open market or private sale	$41,295 $104.28 p/Share	396 Reduced 1.42%	27,417 Common Stock
Mar 02 2021	SELL Open market or private sale	$97,679 $138.16 p/Share	707 Reduced 2.48%	27,813 Common Stock
Mar 01 2021	SELL Open market or private sale	$341,280 $138.17 p/Share	2,470 Reduced 7.97%	28,520 Common Stock
Mar 01 2021	BUY Grant, award, or other acquisition	-	10,136 Added 24.65%	30,990 Common Stock
Oct 14 2020	SELL Open market or private sale	$19,360 $88.0 p/Share	220 Reduced 0.93%	23,370 Common Stock
Jun 03 2020	SELL Open market or private sale	$187,920 $74.69 p/Share	2,516 Reduced 10.77%	20,854 Common Stock

Also insider at

DNLI

Denali Therapeutics Inc. Healthcare

Director

INZY

Inozyme Pharma, Inc. Healthcare

Erik Harris

EVP & Chief Commercial Officer

Novato, CA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells RARE shares.

Notify only if

Value

Insider Trading

Get notified when an Ultragenyx Pharmaceutical Inc. insider buys or sells RARE shares.

Notify only if

Operation

Value

Type

News

Receive news related to Ultragenyx Pharmaceutical Inc.

Track Activities on RARE

Account